Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference
12 mai 2022 08h30 HE
|
Blue Water Vaccines Inc.
CINCINNATI, May 12, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address...
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
09 mai 2022 08h30 HE
|
Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
21 avr. 2022 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter...
Blue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC
21 avr. 2022 08h45 HE
|
Blue Water Vaccines Inc.
CINCINNATI, April 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines, today...
Isothermal Nucleic Acid Amplification Technology Market to cross USD 2.8 Billion by 2028: Global Market Insights Inc.
20 avr. 2022 06h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware , April 20, 2022 (GLOBE NEWSWIRE) -- The isothermal nucleic acid amplification technology (INAAT) market value is projected to reach USD 2.8 billion by 2028, according to a...
Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules
13 avr. 2022 09h30 HE
|
Blue Water Vaccines Inc.
CINCINNATI, April 13, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022
11 avr. 2022 09h56 HE
|
Blue Water Vaccines Inc.
BWV-101 - Universal Influenza Program: Developing a novel vaccine to protect against all influenza strains using groundbreaking mathematical models and research CINCINNATI, April 11, 2022 (GLOBE...
Ebvia Announces Positive Results Published in Nature for TMPRSS2 Inhibitor for the Prevention and Treatment of COVID-19
29 mars 2022 09h00 HE
|
Ebvia
SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) -- Ebvia, a biotechnology developing simple-to-use therapeutics for the treatment and prevention of COVID-19, today announces the publication entitled...
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
23 mars 2022 16h05 HE
|
Cocrystal Pharma, Inc.
Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the treatment of pandemic and seasonal influenza AAdvanced COVID-19 programs with the goal...
Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility
22 mars 2022 07h00 HE
|
Blue Water Vaccines Inc.
Blue Water Vaccines has exclusive, global licensing rights to Cincinnati Children’s Hospital Medical Center’s novel virus-like particle (VLP) vaccine platform.The data supports BWV’s ongoing...